vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2021-2-88-94vtio-1371Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL REPORTSСлучай внутрипортального введения мононуклеарных клеток аутологичного костного мозга и трансплантации печени у пациентки с циррозомA case report on intraportal injection of autologous bone marrow-derived mononuclear cells and liver transplantation in a patient with cirrhosisШералиевА. Р.SheralievA. R.

Шералиев Аслан Рахимджонович

197758, Санкт-Петербург, ул. Ленинградская, д. 70

Aslan Sheraliev

70, Leningradskaya str., St. Petersburg, 197758

sherali.aslan@gmail.comПоликарповА. А.PolikarpovA. A.

Санкт-Петербург

St. Petersburg

ТилеубергеновИ. И.TileubergenovI. I.

Санкт-Петербург

St. Petersburg

МоисеенкоА. В.MoiseenkoA. V.

Санкт-Петербург

St. Petersburg

ГрановД. А.GranovD. A.

Санкт-Петербург

St. Petersburg

ФГБУ «Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова» Минздрава РоссииРоссияGranov Russian Scientific Center of Radiology and Surgical TechnologyRussian Federation2021110720212328894Copyright © Шералиев А.Р., Поликарпов А.А., Тилеубергенов И.И., Моисеенко А.В., Гранов Д.А., 20212021Шералиев А.Р., Поликарпов А.А., Тилеубергенов И.И., Моисеенко А.В., Гранов Д.А.Sheraliev A.R., Polikarpov A.A., Tileubergenov I.I., Moiseenko A.V., Granov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1371

На сегодняшний день единственным эффективным способом лечения пациентов с циррозом является трансплантация печени. В связи с отсутствием других эффективных, альтернативных методов терапии поиск и разработка новых технологий лечения является актуальной проблемой. Развитие клеточных технологий перспективно для использования в клинической практике. На примере данного наблюдения показана безопасность и эффективность технологии клеточной терапии для продленного нахождения пациентки с циррозом в листе ожидания трансплантации печени. После внутрипортального введения мононуклеарных клеток аутологичного костного мозга отмечена стабилизация цирроза печени по шкалам CTP, MELD-Na на протяжении 22 мес. наблюдения, что позволило дождаться донорского органа и успешно выполнить трансплантацию печени.

To date, liver transplantation remains the only effective treatment for patients with cirrhosis. Due to lack of other effective, alternative therapeutic methods, the search and development of new treatment technologies is problem number one. The development of cellular technologies is promising for use in clinical practice. Using this observation as an example, the safety and efficacy of cell therapy technology for prolonged stay on the liver transplant waiting list by a patient with cirrhosis is shown. After intraportal injection of autologous bone marrow-derived mononuclear cells, liver cirrhosis stabilized on the CTP and MELD-Na scales for 22 months of observation, which allowed the patient to wait for an organ and successfully undergo liver transplantation.

мононуклеарные клетки аутологичного костного мозга (МНК)клеточная терапиястволовые клеткивнутрипортальное введениекостный мозгпортофлоуметрияцирроз печенитрансплантация печениautologous bone marrow-derived mononuclear cellscell therapystem cellsintraportal injectionbone marrowportal flowmetryliver cirrhosisliver transplantationReferencesАлександров ВН, Камилова ТА, Калюжная ЛИ, Кривенцов АВ, Фирсанов ДВ, Чирский ВС и др. Клеточная терапия цирроза печени. Вестник Российской военно-медицинской академии. 2014; 1 (45): 197– 202.Аlexandrov VN, Каmilovа ТА, Каlyuzhnaya LI, Кriventzov АV, Firsanov DV, Chirsky VS et al. Cell therapy in liver cirrhosis. Bulletin of the Russian Military Medical Academy. 2014; 1 (45): 197–202. (In Russ.).Ивашкин ВТ, Маевская МВ, Павлов ЧС, Сиволап ЮП, Луньков ВД, Жаркова МС и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (6): 20–40. doi.org/10.22416/1382-4376-2017-27-6-20-40.Ivashkin VT, Mayevskaya MV, Pavlov CS, Sivolap YuP, Lunkov VD, Zharkova MS et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (6): 20–40. (In Russ.). doi.org/10.22416/1382-4376-2017-27-6-20-40.Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017; 152 (5): 1090–1099. doi.org/10.1053/j.gastro.2017.01.003.Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017; 152 (5): 1090–1099. doi.org/10.1053/j.gastro.2017.01.003.Гранов АМ, Гранов ДА, Жеребцов ФК, Герасимова ОА, Боровик ВВ, Осовских ВВ и др. Трансплантация печени в РНЦРХТ. Опыт 100 операций. Вестник трансплантологии и искусственных органов. 2012; 14 (4): 11–16.Granov AM, Granov DA, Zherebtsov FK, Gerasimova OA, Borovik VV, Osovskikh VV et al. Liver Transplantation. A Single Center Experience of 100 Cases. Russian Journal of Transplantology and Artificial Organs. 2012; 14 (4): 11–16. (In Russ.).Готье СВ. Трансплантация печени в России: 25-летний опыт и современные возможности. Вестник трансплантологии и искусственных органов. 2015; 7 (2): 93–95. doi: 10.15825/1995-1191-2015-2-93-95.Gautier SV. Liver Transplantation in Russia: 25-year experience and current solutions. Russian Journal of Transplantology and Artificial Organs. 2015; 7 (2): 93–95. (In Russ). doi: 10.15825/1995-1191-2015-2-93-95.Pais R, Barritt 4th AS, Calmus Y, Scatton O, Runge T, Lebray P et al. NAFLD and liver transplantation: current burden and expected challenges. Journal of hepatology. 2016; 65 (6): 1245–1257. doi.org/10.1016/j.jhep.2016.07.033.Pais R, Barritt 4th AS, Calmus Y, Scatton O, Runge T, Lebray P et al. NAFLD and liver transplantation: current burden and expected challenges. Journal of hepatology. 2016; 65 (6): 1245–1257. doi.org/10.1016/j.jhep.2016.07.033.Готье СВ, Мойсюк ЯГ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2014 году. VII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2015; 17 (2): 7–22. doi.org/10.15825/1995-1191-2015-2-7-22.Gautier SV, Moysyuk YG, Khomyakov SM. Organ Donation and Transplantation in the Russian Federation in 2014 7th Report of National Register. Russian Journal of Transplantology and Artificial Organs. 2015; 17 (2): 7–22. (In Russ.). doi.org/10.15825/1995-1191-2015-2-7-22.Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2017 году. X сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2018. 20 (2): 6–28. doi.org/10.15825/1995-1191-2018-2-6-28.Gautier SV, Khomyakov SM. Organ Donation and Transplantation In Russian Federation In 2017 10th Report of the National Registry. Russian Journal of Transplantology and Artificial Organs. 2018; 20 (2): 6–28. (In Russ.). doi.org/10.15825/1995-1191-2018-2-6-28.Yannaki E, Anagnostopoulos A, Kapetanos D, Xagorari A, Iordanidis F, Batsis I et al. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol. 2006; 34: 1583–1587. doi.org/10.1016/j.exphem.2006.06.012.Yannaki E, Anagnostopoulos A, Kapetanos D, Xagorari A, Iordanidis F, Batsis I et al. Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp Hematol. 2006; 34: 1583–1587. doi.org/10.1016/j.exphem.2006.06.012.Peng L, Xie DY, Lin BL, Liu J, Zhu HP, XieCet al. Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Liver Failure Patients Caused by Hepatitis B: Short-Term and Long-Term Outcomes. Hepatology. 2011; Sept: 820–828. doi.org/10.1002/hep.24434.Peng L, Xie DY, Lin BL, Liu J, Zhu HP, XieCet al. Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Liver Failure Patients Caused by Hepatitis B: Short-Term and Long-Term Outcomes. Hepatology. 2011; Sept: 820–828. doi.org/10.1002/hep.24434.Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018; 3: 25–36. doi.org/10.1016/S2468-1253(17)30326-6.Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018; 3: 25–36. doi.org/10.1016/S2468-1253(17)30326-6.Chung SJ, Lee TY, Lee YH, Baik K, Jung JH, Yoo HS et al. Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. 2020. doi: 10.21203/rs.3.rs-62544/v1.Chung SJ, Lee TY, Lee YH, Baik K, Jung JH, Yoo HS et al. Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. 2020. doi: 10.21203/rs.3.rs-62544/v1.Feng Y, Wang AT, Jia HH, Zhao M, Yu H. A Brief Analysis of Mesenchymal Stem Cells as Biological Drugs for the Treatment of Acute-on-Chronic Liver Failure (ACLF): Safety and Potency. Current Stem Cell Research & Therapy. 2020; 15 (3): 202–210. doi.org/10.2174/1574888X15666200101124317.Feng Y, Wang AT, Jia HH, Zhao M, Yu H. A Brief Analysis of Mesenchymal Stem Cells as Biological Drugs for the Treatment of Acute-on-Chronic Liver Failure (ACLF): Safety and Potency. Current Stem Cell Research & Therapy. 2020; 15 (3): 202–210. doi.org/10.2174/1574888X15666200101124317.Sakai Y, Takamura M, Seki A, Sunagozaka H, Terashima T, Komura T et al. Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell. Regenerative Therapy. 2017; 6: 52–64. doi.org/10.1016/j.reth.2016.12.001.Sakai Y, Takamura M, Seki A, Sunagozaka H, Terashima T, Komura T et al. Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell. Regenerative Therapy. 2017; 6: 52–64. doi.org/10.1016/j.reth.2016.12.001.Am Esch JS 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW et al. Portal Application of Autologous CD133+ Bone Marrow Cells to the Liver: A Novel Concept to Support Hepatic Regeneration. Stem Cells. 2005; 23: 463–470. doi.org/10.1634/stemcells.2004-0283.Am Esch JS 2nd, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW et al. Portal Application of Autologous CD133+ Bone Marrow Cells to the Liver: A Novel Concept to Support Hepatic Regeneration. Stem Cells. 2005; 23: 463–470. doi.org/10.1634/stemcells.2004-0283.Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+cells in patients with chronic liver disease. Cell Proliferation. 2008; 41: 115–125.Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+cells in patients with chronic liver disease. Cell Proliferation. 2008; 41: 115–125.Mahmoud SZ, Abdo EF, Helal SR, Eldien HS, Abdeltawab D, Abd-Elkader AS. Clinical and laboratory outcomes of stem cell transplantation in patients with decompensated liver cirrhosis: single-arm pilot trial. Journal of Current Medical Research and Practice. 2019; 4 (1): 44. doi: 10.4103/JCMRP.JCMRP_30_18.Mahmoud SZ, Abdo EF, Helal SR, Eldien HS, Abdeltawab D, Abd-Elkader AS. Clinical and laboratory outcomes of stem cell transplantation in patients with decompensated liver cirrhosis: single-arm pilot trial. Journal of Current Medical Research and Practice. 2019; 4 (1): 44. doi: 10.4103/JCMRP.JCMRP_30_18.Коткас ИЕ. Изменение гемодинамики печени после ее резекции на фоне применения клеточных технологий. Медицина и здравоохранение в современном обществе: сборник. 2020: 38.Kotkas IE. Changes in the hemodynamics of the liver after its resection with the use of cellular technologies. Medicina i zdravoohraneyie v sovremenom obshestve: Supplement. 2020: 38. (In Russ.).

The authors declare that there are no conflicts of interest present.